Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (03 / 29 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.General Information About Osteosarcoma and Malignant Fibrous Histiocytoma (MFH) of BoneAdded Janeway et al. as reference 52.Recurrent Osteosarcoma and MFH of BoneAdded text to state that abdominal metastases are rare but may occur as late as 4 years after diagnosis (cited Rejin et al. as reference 7).This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Adenoid Cystic Carcinoma
Important It is possible that the main title of the report Adenoid Cystic Carcinoma is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Childhood Soft Tissue Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information
This cancer treatment information summary provides an overview of the prognosis,diagnosis,classification,and treatment of childhood soft tissue sarcoma. The National Cancer Institute provides the PDQ pediatric cancer treatment information summaries as a public service to increase the availability of evidence-based cancer information to health professionals,patients,and the public. These ...
Esophageal Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - What is prevention?
Cancerprevention is action taken to lower the chance of getting cancer. By preventing cancer,the number of new cases of cancer in a group or population is lowered. Hopefully,this will lower the number of deaths caused by cancer. To prevent new cancers from starting,scientists look at risk factors and protective factors. Anything that increases your chance of developing cancer is called a ...
Anal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I Anal Cancer
Stage I anal cancer was formerly treated with abdominoperineal resection. Current sphincter-sparing therapies include wide local excision for small tumors of the perianal skin or anal margin,or definitive chemoradiation (fluorouracil and mitomycin) for cancers of the anal canal. Salvage chemoradiotherapy (fluorouracil and cisplatin plus a radiation boost) may avoid permanent colostomy in ...
Salivary Gland Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Salivary Gland Cancer
For more information from the National Cancer Institute about salivary gland cancer,see the following: Head and Neck Cancer Home Page Oral Complications of Chemotherapy and Head/Neck Radiation Head and Neck Cancer: Questions and Answers For general cancer information and other resources from the National Cancer Institute,see the following: What You Need to Know About™ Cancer - An Overview ...
Cancer Screening Overview (PDQ®): Screening - Health Professional Information [NCI] - Cancer Screening
Cancer Incidence and Mortality In 2006,an estimated 1,399,790 people in the United States will be diagnosed with cancer,and 564,830 will die of cancer.[ 1 ] Estimates of the premature deaths that could have been avoided through screening vary from 3% to 35%,depending on a variety of assumptions. Beyond the potential for avoiding death,screening may reduce cancer morbidity since treatment for ...
PC-SPES (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Overview
PC-SPES is a mixture of 8 herbs that was sold as a dietary supplement to keep the prostate healthy (see Question 1). Some batches of PC-SPES were found to contain prescription medicines. It was taken off the market and is no longer being made (see Question 1). Herbs in PC-SPES have been used in traditional Chinese medicine for many health problems,including prostate problems,for hundreds of ...
Cardiopulmonary Syndromes (PDQ®): Supportive care - Patient Information [NCI] - Current Clinical Trials
Check NCI's list of cancer clinical trials for U.S. supportive and palliative care trials about dyspnea,malignant pleural effusion and malignant pericardial effusion that are now accepting participants. The list of trials can be further narrowed by location,drug,intervention,and other criteria. General information about clinical trials is also available from the NCI Web site. ...
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - High-Stage Childhood Anaplastic Large Cell Lymphoma Treatment
Children and adolescents with high-stage (stage III or IV) anaplastic large cell lymphoma have a disease-free survival of approximately 60% to 75%.[1,2,3,4,5,6] It is unclear which strategy is best for the treatment of high-stage anaplastic large cell lymphoma. The German Berlin-Frankfurt-Munster (BFM) group used six cycles of intensive pulsed therapy, similar to their B-cell non-Hodgkin lymphoma (NHL) therapy (GER-GPOH-NHL-BFM-90 [NHL-BFM-90]).; [Level of evidence: 1iiA] Building on these results, the European Intergroup for Childhood NHL (EICNHL) group conducted the FRE-IGR-ALCL99 study (based on the GER-GPOH-NHL-BFM-90 regimen). First, this randomized study demonstrated that methotrexate 1 g/m2 infused over 24 hours plus intrathecal methotrexate and methotrexate 3 g/m2 infused over 3 hours without intrathecal methotrexate yielded similar outcomes.[Level of evidence: 1iiC] However, methotrexate 3 g/m2 over 3 hours had less toxicity than methotrexate 1 g/m2 over 24